Safety of nirsevimab in children aged 0-24 months: Analysis based on EudraVigilance data (2023-2025).
- 1Pharmacoepidemiology and Pharmacosurveillance Unit, National Centre for Drug Research and Evaluation, Istituto Superiore di Sanità (National Institute of Health), Rome, Italy.
Abstract
Respiratory syncytial virus (RSV) is a cause of severe lower respiratory tract infections in infants, and it is associated with substantial morbidity, including hospitalization and death. After European Medicine Agency approval of nirsevimab, a monoclonal antibody against RSV, immunization campaigns have been implemented in several European Union countries for administration to children as preventive intervention against severe RSV disease during RSV epidemic season. Monitoring its safety in routine healthcare practice is also important. We described suspected adverse drug reactions (ADRs) following nirsevimab administration in children aged 0-24 months, reported in the EudraVigilance system between 2023 and 2025. There were 1,923 ADRs, corresponding to 808 cases. By System Organ Class, ADRs mainly included general disorders and administration site conditions, which include nonspecific systemic manifestations and administration-site reactions that cannot be readily assigned to a single organ system (28.4%), infections and infestations (23.3%), respiratory, thoracic, and mediastinal disorders (12.2%); by Preferred Terms most frequent were drug ineffective (12.6%), and RSV bronchiolitis (9.6%). In addition, pyrexia, rash, and injection site reactions were also common. This study offered systematic characterization of ADRs following administration of nirsevimab. It found that the reported ADRs are consistent with the safety results from pre- and real-world safety studies. Our study can support the continue monitoring of the real-world safety and guide the planning of analytical observational studies on the safety profile of nirsevimab.
Related
- Long-term safety and efficacy of lumacaftor/ivacaftor in children aged ≥12 months of age with cystic fibrosis: a 96-week open-label study
- Effectiveness of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine in Children Aged 6 Months–6 Years During a Statewide Pertussis Outbreak — Alaska, May–November 2024
- Hepatitis B vaccination coverage and factors associated with higher uptake among children aged 5–35 months in eight selected sub-Saharan African countries: a multilevel ordinal logistic regression analysis
- Immunogenicity of fractional one-fifth and one-half doses of 17DD yellow fever vaccine compared with full dose in children aged 9–23 months in Uganda: a phase 4, single-blind, randomised clinical trial
- Prenatal And Postnatal Risk Factors Associated with Stunting in Children Aged 0-24 Months Banyumas Regency Indonesia
BibTeX
@article{morciano2026safety,
title = {{Safety of nirsevimab in children aged 0-24 months: Analysis based on EudraVigilance data (2023-2025).}},
author = {Cristina Morciano and Arianna Annunziata and Maria Cutillo and Flavia Mayer and Stefania Spila Alegiani},
journal = {Human vaccines \& immunotherapeutics},
year = {2026},
month = oct,
doi = {10.1080/21645515.2026.2739001},
url = {https://europepmc.org/article/MED/42851207},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Safety of nirsevimab in children aged 0-24 months: Analysis based on EudraVigilance data (2023-2025).
AU - Cristina Morciano
AU - Arianna Annunziata
AU - Maria Cutillo
AU - Flavia Mayer
AU - Stefania Spila Alegiani
PY - 2026
DA - 2026/10/09
JO - Human vaccines & immunotherapeutics
DO - 10.1080/21645515.2026.2739001
UR - https://europepmc.org/article/MED/42851207
AB - Respiratory syncytial virus (RSV) is a cause of severe lower respiratory tract infections in infants, and it is associated with substantial morbidity, including hospitalization and death. After European Medicine Agency approval of nirsevimab, a monoclonal antibody against RSV, immunization campaigns have been implemented in several European Union countries for administration to children as preventive intervention against severe RSV disease during RSV epidemic season. Monitoring its safety in routine healthcare practice is also important. We described suspected adverse drug reactions (ADRs) following nirsevimab administration in children aged 0-24 months, reported in the EudraVigilance system between 2023 and 2025. There were 1,923 ADRs, corresponding to 808 cases. By System Organ Class, ADRs mainly included general disorders and administration site conditions, which include nonspecific systemic manifestations and administration-site reactions that cannot be readily assigned to a single organ system (28.4%), infections and infestations (23.3%), respiratory, thoracic, and mediastinal disorders (12.2%); by Preferred Terms most frequent were drug ineffective (12.6%), and RSV bronchiolitis (9.6%). In addition, pyrexia, rash, and injection site reactions were also common. This study offered systematic characterization of ADRs following administration of nirsevimab. It found that the reported ADRs are consistent with the safety results from pre- and real-world safety studies. Our study can support the continue monitoring of the real-world safety and guide the planning of analytical observational studies on the safety profile of nirsevimab.
SN - 2164-5515
SN - 2164-554X
ER -